Vitamin B12 1000 μg

DIETARY_SUPPLEMENT5 trials

Conditions

KEAP1 Gene MutationMetastatic Non-squamous Non Small Cell Lung CancerNFE2L2 Gene MutationNRF2 Gene MutationNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaNon-Squamous Non-Small Cell Neoplasm of LungNon-squamous NSCLC

Phase 2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

TerminatedNCT04265534

Calithera Biosciences, IncKEAP1 Gene Mutation, NFE2L2 Gene Mutation, Non-Small Cell Lung Cancer +3

Start: 2020-07-24End: 2022-02-09Updated: 2022-09-21

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Active, not recruitingNCT05751187

Shanghai Chest HospitalNon-squamous NSCLC

Start: 2023-06-27End: 2027-12-30Target: 54Updated: 2026-03-11

Phase 3

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

CompletedNCT02578680

Merck Sharp & Dohme LLCNon-Small-Cell Lung Carcinoma

Start: 2016-01-15End: 2023-06-22Updated: 2024-09-20

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

CompletedNCT03950674

Merck Sharp & Dohme LLCNon-Small-Cell Lung Carcinoma

Start: 2016-02-22End: 2023-06-22Updated: 2024-06-10

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

TerminatedNCT04786964

Checkpoint Therapeutics, Inc.Metastatic Non-squamous Non Small Cell Lung Cancer

Start: 2021-12-08End: 2023-12-30Updated: 2025-04-02

2025-06-11

Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.

2024-10-2728 citations

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

Journal of Thoracic Oncology2024-04-1834 citations

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Nature Communications2023-11-1124 citations

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Journal of Clinical Oncology2023-02-21530 citations

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.

2022-11-0826 citations

581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC

Regular and Young Investigator Award Abstracts2022-11-01

External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.

2022-08-0210 citations

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

Regular and Young Investigator Award Abstracts2021-11-01

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.

2021-04-22311 citations

Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.

2021-02-1911 citations

Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer.

2021-01-013 citations

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer2020-09-11107 citations

Abstract LB-397: Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 by <i>STK11</i> and <i>KEAP1</i> status

Cancer Research2020-08-1516 citations

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2020-05-2025 citations

Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

Journal of Clinical Oncology2020-05-2024 citations

A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).

Journal of Clinical Oncology2020-05-206 citations

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Journal of Clinical Oncology2020-03-091122 citations

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

2020-02-06164 citations

Pemetrexed (Pem) with pembrolizumab (Pembro) maintenance: A post hoc subgroup safety analysis of KEYNOTE-189.

Journal of Clinical Oncology2020-02-041 citations

8 more papers not shown

Vitamin B12 1000 μg

Sponsors

Conditions

Phase 2

Phase 3

Related Papers